Liver transplantation (LT) for hepatocellular carcinoma (HCC), applying restrictive criteria (i.e. tumour size <5 cm, less than three nodules, no vascular invasion), has yielded improving results with 3-year survival rates over 65% and 5-year survival rates better than 45%. Using living donor liver transplantation (LDLT) a substantial survival advantage for patients with non-resectable early stage HCC can be expected. The procedure does not exploit the pool of cadaveric organs and allows for an earlier time of transplantation. We therefore raise the subject to expand criteria for LDLT in patients with HCC.
展开▼
